Cytokinetics Weighted Average Shares Diluted Trend from 2010 to 2022

CYTK
 Stock
  

USD 47.25  0.05  0.11%   

Cytokinetics Weighted Average Shares Diluted is increasing with slightly volatile movements from year to year. Weighted Average Shares Diluted is predicted to flatten to about 65.6 M. For the period between 2010 and 2022, Cytokinetics, Weighted Average Shares Diluted quarterly trend regression had mean deviation of 17,305,274 and r-value of  0.98. Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million.
  
Refresh
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics main balance sheet or income statement drivers, such as Gross Profit of 59.3 M, Interest Expense of 17.7 M or Operating Expenses of 277 M, as well as many exotic indicators such as Interest Coverage of 7.48, Long Term Debt to Equity of 0.56 or PPandE Turnover of 1.67. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules. It can also supplement various Cytokinetics Technical models. Continue to the analysis of Cytokinetics Correlation against competitors.

Cytokinetics Quarterly Weighted Average Shares Diluted

85 Million

Share

Cytokinetics Weighted Average Shares Diluted Breakdown

Showing smoothed Weighted Average Shares Diluted of Cytokinetics with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPSDil]; determined based on the timing of issuance of shares or units in the period.Cytokinetics' Weighted Average Shares Diluted historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
Weighted Average Shares Diluted10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares Diluted 
Share
      Timeline 

Cytokinetics Weighted Average Shares Diluted Regression Statistics

Arithmetic Mean 42,650,041
Geometric Mean 36,502,656
Coefficient Of Variation 49.68
Mean Deviation 17,305,274
Median 42,561,000
Standard Deviation 21,189,925
Range 65,086,000
R-Value 0.98
R-Squared 0.96
Significance 0
Slope 5,344,303

Cytokinetics Weighted Average Shares Diluted History

201218.1 M
201327.3 M
201435.7 M
201538.8 M
201642.6 M
201749.4 M
201854.4 M
201957.6 M
202064.5 M
202176.9 M
202265.6 M

About Cytokinetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytokinetics income statement, its balance sheet, and the statement of cash flows. Cytokinetics investors use historical funamental indicators, such as Cytokinetics's Weighted Average Shares Diluted, to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytokinetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytokinetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Weighted Average Shares Diluted76.9 M65.6 M
Average Assets702.6 M758 M
Average Equity144.3 M116.7 M
Invested Capital Average814.8 M879.1 M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Cytokinetics Correlation against competitors. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.